DBI 002
Alternative Names: DBI-002Latest Information Update: 30 Sep 2022
At a glance
- Originator DermBiont
- Class Anti-inflammatories; Antifungals; Foot disorder therapies; Skin disorder therapies
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Atopic dermatitis; Onychomycosis; Pityriasis versicolor; Seborrhoeic dermatitis; Tinea pedis
Most Recent Events
- 21 Sep 2022 DermBiont suspends a Phase II trial in Onychomycosis (Topical) in USA due to sponsors decision and not due to safety or site-related matters (NCT05491603)
- 08 Aug 2022 Phase-II clinical trials in Tinea pedis in USA (Topical) (NCT05493488)
- 01 Jun 2022 Phase-II clinical trials in Atopic dermatitis in USA (Topical) (DermBiont pipeline, June 2022)